Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Short-term Investments (2023 - 2025)

Historic Short-term Investments for GeneDx Holdings (WGS) over the last 3 years, with Q3 2025 value amounting to $59.1 million.

  • GeneDx Holdings' Short-term Investments rose 93.06% to $59.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 93.06%. This contributed to the annual value of $56.0 million for FY2024, which is 8371.68% up from last year.
  • Per GeneDx Holdings' latest filing, its Short-term Investments stood at $59.1 million for Q3 2025, which was up 93.06% from $60.4 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Short-term Investments peaked at $60.4 million during Q2 2025, and registered a low of $12.1 million during Q1 2023.
  • In the last 3 years, GeneDx Holdings' Short-term Investments had a median value of $53.4 million in 2024 and averaged $44.3 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first surged by 14076.91% in 2024, then surged by 93.06% in 2025.
  • Quarter analysis of 3 years shows GeneDx Holdings' Short-term Investments stood at $30.5 million in 2023, then skyrocketed by 83.72% to $56.0 million in 2024, then increased by 5.61% to $59.1 million in 2025.
  • Its Short-term Investments was $59.1 million in Q3 2025, compared to $60.4 million in Q2 2025 and $59.5 million in Q1 2025.